CCL2 and cardiovascular disorder: Circulating levels of MCP‐1 are increased in patients with renal disease (Akdogan et al., 2015), cognitive impairment and Alzheimer's disease (Bettcher et al., 2016), atherosclerosis and cardiovascular disease (Deo et al., 2004).